225 related articles for article (PubMed ID: 10558581)
21. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Jun; 75(124):37295-9. PubMed ID: 20608285
[TBL] [Abstract][Full Text] [Related]
22. Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans- tetrahydrocannabinol (delta-9-THC)] in Schedule II. Final rule.
Drug Enforcement Administration, Department of Justice.
Fed Regist; 2017 Nov; 82(224):55504-6. PubMed ID: 29232070
[TBL] [Abstract][Full Text] [Related]
23. Schedules of controlled substances: removal of naloxegol from control. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Jan; 80(15):3468-70. PubMed ID: 25730920
[TBL] [Abstract][Full Text] [Related]
24. Schedules of Controlled Substances: Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Sep; 80(176):54715-8. PubMed ID: 26364325
[TBL] [Abstract][Full Text] [Related]
25. Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2014 Aug; 79(167):51243-7. PubMed ID: 25167596
[TBL] [Abstract][Full Text] [Related]
26. Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order.
Drug Enforcement Administration. Department of Justice
Fed Regist; 2013 Nov; 78(221):68716-9. PubMed ID: 24236337
[TBL] [Abstract][Full Text] [Related]
27. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2014 Feb; 79(27):7577-82. PubMed ID: 24605391
[TBL] [Abstract][Full Text] [Related]
28. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2011 Dec; 76(241):77895-99. PubMed ID: 22175093
[TBL] [Abstract][Full Text] [Related]
29. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
[TBL] [Abstract][Full Text] [Related]
30. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
[TBL] [Abstract][Full Text] [Related]
31. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
[TBL] [Abstract][Full Text] [Related]
32. Designation of oripavine as a basic class of controlled substance. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
[TBL] [Abstract][Full Text] [Related]
33. Schedules of controlled substances: temporary placement of 10 synthetic cathinones into Schedule I. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2014 Mar; 79(45):12938-43. PubMed ID: 24611212
[TBL] [Abstract][Full Text] [Related]
34. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Jan; 80(20):5042-7. PubMed ID: 25730924
[TBL] [Abstract][Full Text] [Related]
35. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
[TBL] [Abstract][Full Text] [Related]
36. Schedules of Controlled Substances: Placement of Eluxadoline Into Schedule IV. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Nov; 80(218):69861-4. PubMed ID: 26567437
[TBL] [Abstract][Full Text] [Related]
37. Schedules of Controlled Substances: Temporary Placement of Acetyl Fentanyl Into Schedule I. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2015 Jul; 80(137):42381-5. PubMed ID: 26189217
[TBL] [Abstract][Full Text] [Related]
38. Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2018 Sep; 83(189):48950-3. PubMed ID: 30272400
[TBL] [Abstract][Full Text] [Related]
39. Schedules of controlled substances; table of excluded nonnarcotic products: nasal decongestant inhalers manufactured by Classic Pharmaceuticals, LLC. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Mar; 75(55):13678-9. PubMed ID: 20383920
[TBL] [Abstract][Full Text] [Related]
40. Facsimile transmission of prescriptions for patients enrolled in hospice programs. Drug Enforcement Administration (DEA), Justice. Final rule.
Fed Regist; 2001 Jan; 66(8):2214-5. PubMed ID: 11503757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
